基于SNP的cfDNA筛查非典型结果的妊娠结局:人群队列研究
非典型结果组胎儿染色体异常风险显著高于低风险组(校正相对风险36.3,95%CI 28.1-47.0),且风险因非典型结果亚型而异,从 maternal 亚组的2.9%到与常见非整倍体高风险结果同时报告的100.0%。
要点
- 基于SNP的cfDNA筛查非典型结果发生率为0.8%。
- 非典型结果妊娠染色体异常风险是低风险妊娠的36.3倍。
- 非典型结果亚型不同,染色体异常风险从2.9%至100.0%不等。
核心结论
- 基于SNP的cfDNA筛查非典型结果的妊娠染色体异常风险显著升高,且风险因结果亚型而异。
主要发现
- 415例(0.8%)妊娠出现非典型结果。
- 在进行了细胞遗传学检测或记录活产的妊娠中,18.2%发现胎儿染色体异常。
- 非典型结果亚组的染色体异常比例:母源型2.9%,未指定型15.2%,胎儿型24.2%,与常见非整倍体高风险结果同时报告者达100.0%。
- 非典型结果妊娠染色体异常风险较低风险结果妊娠高36.3倍(校正相对风险36.3,95%CI 28.1-47.0)。
关键数值与推荐
- 非典型结果定义为基于SNP的cfDNA平台报告的不可报告结果新类别,提示DNA分析中额外或意外发现。
- 关联分析使用改良泊松回归模型,校正母亲年龄、孕龄和受孕方式。
临床怎么用
- 临床医生应告知非典型cfDNA结果妊娠的染色体异常风险升高,且风险因亚型而异,需个体化咨询。
- 对于非典型结果,尤其合并常见非整倍体高风险结果时,应建议进一步遗传学评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cell-free DNA (cfDNA) screening has transformed prenatal screening by offering superior performance for detecting common aneuploidies, though it occasionally yields nonreportable or uninterpretable results. In 2020, a SNP-based cfDNA platform introduced a new category of nonreportable results termed "atypical," indicating additional or unexpected findings during DNA analysis. The clinical significance of these atypical results remains unclear, leaving clinicians without evidence-based guidance for counseling of pregnant individuals in the context of such results. OBJECTIVES: This study aimed to evaluate the association between atypical results and fetal chromosomal abnormalities. Our objectives were to estimate the incidence of atypical results, describe the characteristics of pregnancies with such results, and report on fetal/neonatal chromosomal abnormalities and pregnancy outcomes. STUDY DESIGN: This was a population-based cohort study of all singleton pregnancies in Ontario with an estimated date of delivery from October 1, 2020, to December 31, 2023, with SNP-based cfDNA screening. The study was conducted using data from Ontario's prescribed perinatal registry, Better Outcomes Registry & Network. Pregnancies with atypical cfDNA results were compared to those with low-risk results for chromosomal abnormalities and pregnancy outcomes. Additionally, subgroups of atypical results were identified and analyzed separately: (1) origin reported as fetal, (2) origin reported as maternal, (3) origin unspecified, and (4) atypical results reported alongside a high-risk result for a common aneuploidy. Associations were evaluated using a modified Poisson regression model, with adjustments for maternal age, gestational age, and conception type. RESULTS: The study included 53,283 singleton pregnancies with SNP-based cfDNA screening, among which 415 (0.8%) had an atypical result. Among the pregnancies with atypical results in which cytogenetic testing was performed, or for those in which a live birth was recorded, 18.2% were found to have a fetal chromosomal abnormality, ranging from 2.9% in the maternal atypical result group, 15.2% in the unspecified atypical result group, 24.2% for fetal atypical results and up to 100.0% for atypical results that were reported along with a high-risk result for a common aneuploidy. The risk of chromosomal abnormalities in a pregnancy with an atypical result was 36.3 times higher (adjusted relative risk 36.3, 95% confidence interval 28.1-47.0), compared to a pregnancy with low-risk results. CONCLUSIONS: Pregnancies with atypical cfDNA results showed an increased risk of chromosomal abnormalities, which varied by result subtype. This study is the first to report on the incidence of atypical results in the SNP-based cfDNA screening platform, and their association with chromosomal abnormalities on a population-level, thereby providing a foundation for evidence-based counseling and future research. El resumen está disponible en Español al final del artículo.
引用
- Bellai-Dussault K, Dougan SD, Okun N, et al. Investigating the outcomes of pregnancies with atypical results following SNP-based cfDNA screening: a population-based cohort study. Am J Obstet Gynecol MFM. 2026. PMID: 42476502. doi:10.1016/j.ajogmf.2026.102062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。